Eli Lilly and Company (LLY) stock plummeted on Wednesday after the pharmaceutical giant reported weaker-than-expected third-quarter earnings and slashed its 2024 guidance. The company attributed the decline to increased research and development (R&D) costs and a decline in Trulicity sales. Despite a 20% year-over-year revenue increase, the company missed analysts’ expectations, leading to a significant drop in its stock price.
Eli Lilly has filed lawsuits against medical spas and online vendors for allegedly selling unauthorized versions of tirzepatide, the active ingredient in its weight-loss medication, Zepbound. This action comes despite the recent resolution of the FDA-declared tirzepatide injection shortage. Eli Lilly argues that these vendors are offering counterfeit products without FDA approval and are engaging in misleading advertising practices.
The FDA is reconsidering its decision to ban compounding pharmacies from supplying cheaper versions of Eli Lilly’s blockbuster weight loss and diabetes drugs, Mounjaro and Zepbound. This comes after a lawsuit filed by compounding groups challenging the FDA’s restriction. Eli Lilly has also issued cease-and-desist letters to companies offering similar products, citing potential safety concerns.
The NHS in England is planning a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to see significant clinical outcomes. The drug, which has shown impressive results in trials, will be made available through community-based services and digital health platforms, with the goal of reaching 240,000 people over the first three years. The plan is currently under consultation, with final guidance from NICE expected later this year.
Eli Lilly is taking action to combat the growing competition from compounding pharmacies offering cheaper versions of its popular weight loss drugs, Mounjaro and Zepbound. The company is pushing to remove the FDA shortage designation, highlighting patient safety concerns with off-brand alternatives and launching its own discounted product to meet demand.
A US judge’s decision in a multidistrict litigation involving diabetes and weight-loss drugs could significantly impact the course of lawsuits against Novo Nordisk and Eli Lilly. The ruling allows for early resolution of key legal questions, potentially streamlining or halting the litigation before it progresses. The plaintiffs claim the drugs caused gastroparesis, but the companies argue their labels adequately warn of potential gastrointestinal side effects.
Mounjaro, a new injectable medication, is gaining popularity for its effectiveness in weight loss. While it’s licensed to treat type 2 diabetes, its ability to mimic two hormones makes it more effective than Ozempic and Wegovy. However, the surge in demand for weight loss has led to shortages for diabetics, and experts warn about potential side effects and the importance of lifestyle changes.
Eli Lilly’s popular obesity and diabetes drugs, Mounjaro and Zepbound, are facing ongoing shortages that are limiting their supply and impacting the company’s earnings. According to analysts, these shortages could result in lower revenue and earnings per share for the first quarter. The company is working to ramp up manufacturing to meet the demand, but the impact on earnings remains a concern. Investors will be watching for updates on manufacturing capacity, pricing, and coverage decisions from insurers as they assess the impact on Lilly’s financial performance.
Women with infertility issues are getting pregnant while taking weight-loss medications Ozempic and Mounjaro, raising safety concerns during pregnancy. These GLP-1 drugs are mainly used to manage blood sugar levels in people with type 2 diabetes and for obesity treatment, but their impact on pregnancy is still largely unknown. Despite encouraging stories, experts emphasize the need for more data on the drugs’ safety and long-term effects on pregnancy outcomes, particularly in women without diabetes. Researchers are conducting studies to understand the drugs’ potential role in treating PCOS, a leading cause of infertility, but companies have yet to systematically study their use for this condition.
TNT’s halftime antics took a funny turn when Charles Barkley revealed he’s using Mounjaro for weight loss, leading to a chorus of advice from the crew. Prior to Game 2, the prank continued with a kale shower and Shaq’s attempted force-feeding, much to Barkley’s dismay.
